Top Markets
Coin of the day
DelMar Pharmaceuticals, Inc. DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc.

DMPWW
Rank in Stocks #42376
Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc.... Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.
Share Price
$0.005
Last synced: 2024-06-20
Market Cap
$1.74K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade DelMar Pharmaceuticals, Inc. (DMPWW)

Category

EPS for DelMar Pharmaceuticals, Inc. (DMPWW)
EPS as of 2026 TTM: 0
According to DelMar Pharmaceuticals, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for DelMar Pharmaceuticals, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
- -
CH
$13.70 -
BE
- -
KR